Table I.

Characteristics of the patients included in these analyses at the time of these enrolment into the EPIC study.

Characteristic	All regions (n=1558)	Europe (n=680)	Middle East/Africa (n=275)	Asia-Pacific (n=603)
Number of patients
TM	937	281	240	416
TI	84	21	7	56
MDS	341	293	3	45
AA	116	29	5	82
SCD	80	56	20	4
Mean age (range), years
TM	18.4 (2–72)	24.9 (2–72)	14.5 (2–43)	16.2 (2–65)
TI	19.2 (4–70)	34.7 (5–70)	12.4 (4–28)	14.3 (4–45)
MDS	67.9 (11–89)	68.8 (11–89)	62.7 (33–78)	62.4 (18–86)
AA	33.3 (2–79)	36.1 (2–79)	18.2 (3–42)	33.2 (7–67)
SCD	23.9 (4–60)	26.9 (9–51)	12.7 (4–41)	36.5 (22–60)
Male:female, n (% male)
TM	450:487 (48)	126:155 (45)	124:116 (52)	200:216 (48)
TI	46:38 (55)	15:6 (71)	2:5 (29)	29:27 (52)
MDS	204:137 (60)	178:115 (61)	2:1 (67)	24:21 (53)
AA	67:49 (58)	16:13 (55)	2:3 (40)	49:33 (60)
SCD	39:41 (49)	26:30 (46)	9:11 (45)	4:0 (100)
Race (Caucasian:Oriental:Other), n
TM	441:452:44	234:9:38	168:69:3	39:374:3
TI	26:54:4	18:1:2	6:1:0	2:52:2
MDS	309:30:2	290:1:2	0:3:0	19:26:0
AA	32:80:4	29:0:0	0:1:4	3:79:0
SCD	18:15:47	8:2:46	7:13:0	3:0:1
History of hepatitis B and/or C, n (%)
TM	258 (27.5)	122 (43.4)	59 (24.6)	77 (18.5)
TI	8 (9.5)	3 (14.3)	1 (14.3)	4 (7.1)
MDS	11 (3.2)	10 (3.4)	0 (0)	1 (2.2)
AA	8 (6.9)	2 (6.9)	0 (0)	6 (7.3)
SCD	19 (23.8)	12 (21.4)	6 (30.0)	1 (25.0)
Splenectomy, n (%)
TM	333 (35.5)	101 (35.9)	110 (45.8)	122 (29.3)
TI	28 (33.3)	17 (81.0)	2 (28.6)	9 (16.1)
MDS	13 (3.8)	10 (3.4)	0 (0)	3 (6.7)
AA	0 (0)	0 (0)	0 (0)	0 (0)
SCD	22 (27.5)	13 (23.2)	9 (45.0)	0 (0)

Legend

TM: thalassaemia major; TI: thalassaemia intermedia; MDS: myelodysplastic syndromes; AA: aplastic anaemia; SCD: sickle cell disease.